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        The            TCR is a multimeric complex consist-
ing of a clonotypic TCR           heterodimer, the 
CD3           and/or CD3           dimer, and the            dimer. 
Because            TCR signaling regulates the com-
mitment of double-negative (CD4        CD8        ) cells 
to the            T cell lineage and is required for their 
subsequent diff  erentiation into mature            T cells, 
the development of           T cells depends on the ex-
pression of the            TCR. Indeed, neither CD3     - 
nor CD3     -defi  cient mice have            T cells (  1  –  3  ). 
Although the overall structure and function of 
the            TCRs in mice and humans are quite 
similar, ablation of the highly related CD3      and 
CD3      subunits has markedly diff  erent eff  ects 
in these two species. Hence,            T cell develop-
ment is severely impaired in CD3     -defi  cient 
mice but not in their human counterparts (  3, 4  ). 
Conversely, CD3      defi  ciency results in a block 
in human, but not mouse,            T cell develop-
ment (  5, 6  ). 
  In contrast to the            TCR, the            TCR has 
been studied extensively and its minimal stoichi-
ometry is proposed to be TCR          CD3       2                   2   
in mice and humans (  7, 8  ). Unlike the mouse 
           TCR, mouse            TCR does not incorporate 
CD3      even if this subunit is expressed intra-
cellularly (  9, 10  ), explaining why            T cells 
develop normally in CD3     -defi  cient mice (  6  ). 
Interestingly, the composition of the mouse            
TCR complex changes in activated cells: a dif-
ferentially glycosylated form of CD3      becomes 
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  The            T cell receptor for antigen (TCR) comprises the clonotypic TCR          , the CD3 (CD3           
and/or CD3          ), and the            dimers.            T cells do not develop in CD3     -defi  cient mice, 
whereas human patients lacking CD3      have abundant peripheral blood            T cells express-
ing high            TCR levels. In an attempt to identify the molecular basis for these discordant 
phenotypes, we determined the stoichiometries of mouse and human            TCRs using blue 
native polyacrylamide gel electrophoresis and anti-TCR  –  specifi  c antibodies. The            TCR 
isolated in digitonin from primary and cultured human            T cells includes CD3     , with a 
TCR          CD3       2                   2   stoichiometry. In CD3     -defi  cient patients, this may allow substitution of 
CD3      by the CD3      chain and thereby support            T cell development. In contrast, the 
mouse            TCR does not incorporate CD3      and has a TCR          CD3       2         2         2   stoichiometry. 
CD3     -defi  cient mice exhibit a block in            T cell development. A human, but not a mouse, 
CD3      transgene rescues            T cell development in mice lacking both mouse CD3      and CD3      
chains. This suggests important structural and/or functional differences between human 
and mouse CD3      chains during            T cell development. Collectively, our results indicate that 
the different            T cell phenotypes between CD3     -defi  cient humans and mice can be 
explained by differences in their            TCR composition. 2538 STOICHIOMETRY OF THE          TCR | Siegers et al.
http://www.jem.org/cgi/content/full/jem.20070782/DC1). 
This was done for all experiments in which            T cell clones 
were used. In the fi  rst experiment, we lysed human            as well 
as            T cell clones and immunopurifi  ed the TCRs with anti-      
incorporated into the receptor (  9  ) and       can be substituted by 
the FcR      chain (  10  ). 
  Contradictory fi  ndings have been reported concerning 
human            TCR stoichiometry. Primary human            T cells 
were found to incorporate little or no CD3      into their surface 
           TCRs (  10  ). In contrast, human            T cell clones and lines 
were found to possess both CD3           and CD3           dimers (  11, 12  ). 
In light of the reported activation-induced changes in mouse 
           TCR composition, it is possible that although CD3      is not 
incorporated into TCRs of naive human            T cells, this chain 
becomes part of the receptor on            T cell clones that have un-
dergone activation and expansion. 
  In this study, we use blue native PAGE (BN-PAGE) and 
specifi  c anti-CD3 antibodies to determine the stoichiometries 
of human and mouse            TCRs. These data are complemented 
by studies on the human CD3      (hCD3     ) defi  ciency pheno-
type, as well as those of CD3          -defi  cient mice supplemented 
with mouse or hCD3      transgenes. In conclusion, we show that 
there are diff  erences in the stoichiometries and, thus, subunit 
requirements for the assembly of mouse and human            TCRs. 
    RESULTS AND DISCUSSION   
                   T cells with high levels of                    TCR are present 
in CD3     -defi  cient   patients 
  In CD3      knockout (CD3            /      ) mice,            T cell development 
is blocked (  3  ); however, this is not the case in CD3     -defi  cient 
humans. We have studied four CD3     -defi  cient patients (  13, 14  ), 
including one  20 yr old, and consistently found that            
T cells are present in their peripheral blood (  Fig. 1 A  ).   As is 
the case with            T cells, the number of            T cells in these 
patients was at or just below the lower limit (P5) of healthy 
CD3     -suffi   cient controls. In the absence of CD3     , CD3 ex-
pression by            T cells is reduced to     20% of that of healthy 
controls (  4  ). However, when we analyzed            T cells from 
these patients by fl  ow cytometry using anti-CD3 antibodies, 
we found that the amount of            TCR per T cell was only re-
duced to 30  –  55% of healthy individuals, depending on the 
antibody used (  Fig. 1, B and C  ). These data show that hCD3      
can compensate, at least partially, for the lack of hCD3      in as-
sembly and surface transport of the human            TCR. In fact, 
in the absence of CD3     , these processes appear to occur more 
effi   ciently in            T cells than in            T cells. As a consequence, 
           T cells can develop in CD3     -defi  cient patients, indicating 
that hCD3      can functionally replace hCD3      to promote            
T cell development. In conclusion, the human            TCR can 
assemble and signal for selection effi   ciently without hCD3     . 
  The human            TCR includes CD3      
  The diff  erent subunit requirements for            T cell development 
in mice and humans could refl  ect distinct            TCR subunit 
composition in these species. To clarify the composition of the 
human            TCR, we used established human            T cell clones 
as well as primary            T cells. Because our            T cell clones 
contained     5% residual irradiated feeder cells expressing the 
           TCR, we depleted            TCRs after cell lysis by immuno-
purifi  cation with anti-TCR      antibodies (Fig. S1, available at 
  Figure 1.     CD3     -defi  cient patients show abundant peripheral blood 
           T cells with high levels of            TCR. (A) Presence of          T cells in 
hCD3      defi  ciency. Peripheral blood cell counts from four CD3    -defi  cient 
individuals are plotted as a function of age in comparison with the 
normal distribution (dashed line). Three were homozygous for a p.K69X 
mutation (triangles), and one was compound heterozygous for p.M1V and 
p.N28V/H29X (squares). CD3    -defi  cient patients (circles) are included for 
comparison. Filled symbols identify SCID patients, who died before 1 yr of 
age. (B) CD3 expression is higher on CD3    -defi  cient          than          T  cells. 
Flow cytometry histograms of anti-CD3 (SK7)  –  stained CD3    -defi  cient 
T cells (dashed lines) are compared with healthy controls (continuous lines) 
either in          (CD8 and CD4; top and middle) or          (double negative; bottom) 
T cells. Numbers indicate TCR expression (mean fl  uorescence intensity) 
on cells from CD3    -defi  cient patients as a percentage of that on cells 
from healthy donors. The vertical dashed line indicates the background 
fl  uorescence using an irrelevant antibody. (C) Quantifi  cation of the CD3 
expression on the indicated cell types from CD3    -defi  cient patients as 
a percentage of that on the same cell types from healthy donors 
(percentage of CD3 expression). Data are expressed as the percent mean 
fl  uorescence intensity       SEM from three different patients using the 
anti-CD3 antibodies SK7 (left) or UCHT1 (right). Similar results were ob-
tained using other anti-CD3 antibodies, as well as other gating criteria 
(not depicted). *, P       0.05 compared with          T  cells.   JEM VOL. 204, October 29, 2007  2539
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glycosylation is intrinsic to the            TCR and not caused by 
diff  erent cellular environments of           and           T cells. Incorpor-
ation of CD3      into the            TCRs of human clones and cell 
lines was confi  rmed by anti-CD3      immunoprecipitation and 
subsequent anti-      Western blotting (Fig. S1 and not depicted). 
This is in line with earlier reports using            T cell clones and 
lines (  11, 12  ). When primary human            T cells were used, 
CD3      could not be detected (  10  ); however, the composition 
of the mouse            TCR changed upon cultivation of primary 
           T cells such that       was replaced by FcR      (  10  ). Likewise, 
the TCR of primary human            T cells might not contain CD3      
but may incorporate it during cultivation. 
  To determine whether CD3      is present in the            TCR of 
primary human T cells, we lysed PBMCs from a healthy do-
nor and purifi  ed            and            TCRs with anti-TCR      and anti-
TCR           antibodies, respectively. Purifi  ed proteins were left 
untreated or deglycosylated and separated by SDS-PAGE 
(  Fig. 2 C  ). Jurkat cells were used as a control. Indeed, the            
antibodies. After nonreducing SDS-PAGE, purifi  ed proteins 
were detected using anti-CD3      and anti-      antibodies (  Fig. 2 A  ).   
The            TCR of the            T cell line Jurkat and the            clones 
          B6 and           PA (lanes 2  –  4), as well as the            TCR of clones 
          19 and           46 (lanes 5 and 6), all contained CD3     . The re-
duced electrophoretic mobility of CD3      associated with the            
TCR could be caused by more complex glycosylation (  11  ). 
To test this, we treated purifi  ed TCRs with N-glycosidase F, 
which cleaves N-linked carbohydrate moieties. Indeed, the 
de  glycosylated forms of            TCR  –   and            TCR  –  associated 
CD3      are the same size (  Fig. 2 B  , lanes 2, 4, and 6). This clearly 
indicates that the            TCR expressed on human            clones 
contains CD3     . 
  To identify the cause of this diff  erential glycosylation, we 
used an            TCR  –  defi  cient variant of Jurkat stably expressing 
transfected TCRV     9 and V     2 chains, named J     9     2 (  15  ). The 
CD3      of J     9     2 had a similar mobility to CD3      in the            
clones (  Fig. 2 B  , lanes 5 and 7). Therefore, the complex CD3      
  Figure 2.     The human            TCR includes CD3     . (A) Human          T cell clones incorporate CD3      into  the          TCR.  Anti-     immunopurifi  ed TCRs from Jurkat, 
         (       B6 and         PA), and          (       19 and         46) T cell clones were separated on nonreducing SDS-PAGE and analyzed via Western blotting using anti-
CD3      and anti-      antibodies. In the control (C), which was loaded on another gel, anti-      antibodies and protein G  –  coupled sepharose were incubated in 
lysis buffer alone. (B)          TCR –   and          TCR – associated  CD3     chains are differentially glycosylated. Anti-      immunopurifi  ed TCRs from          (      B6  and 
        PA) and          (       19) T cell clones, as well as the Jurkat variant J    9    2, were left untreated (     ) or subject to N-glycosidase F treatment ( ) and analyzed 
as in A. Glycosylated (CD3     ) and deglycosylated (dg-CD3    )  CD3     chains are indicated by arrowheads. (C) The          TCR on primary human          T cells con-
tains CD3     . TCRs from Jurkat and human PBMCs were immunopurifi  ed using anti-TCR      and  anti-TCR        antibodies and subjected to deglycosylation and 
analysis as in B.     2540 STOICHIOMETRY OF THE          TCR | Siegers et al.
each antibody molecule bound to the complex produces a 
discrete change in electrophoretic mobility. At nonsaturating 
antibody concentrations, a partial shift, indicating            TCR 
bound to only one antibody (TCR Ab) and cross-linked 
products, in which one antibody bound to two TCRs (marked 
with X), were observed (lanes 2 and 3). These data show that 
the human            TCR incorporates two CD3 dimers. 
  To verify the specifi  city of anti-CD3      and anti-CD3      
antibodies, we expressed individual mouse and human TCR 
subunits in   Drosophila   S2 cells and performed subsequent 
immunopurifi  cations, verifying antibody specifi  city for HMT3.2 
(anti-hCD3     ) and APA1/2 (anti-hCD3     ; Fig. S2 A, available 
at http://www.jem.org/cgi/content/full/jem.20070782/DC1). 
Using these antibodies in the NAMOS assay revealed that one 
copy each of CD3      and CD3      are present in the human            
TCR (  Fig. 3 B  , lanes 5  –  8). This is in agreement with the fact 
that CD3      pairs with either CD3      or CD3      (  18  ). An anti-
TCR           antibody produced only one shift, whereas anti-      
produced two shifts (lanes 9  –  14). Although       is a homodimer, 
the antibody could not bind twice to most            TCRs (lane 12). 
This is caused by steric hindrance, because       is very small 
(16 kD) (  8  ). The same band patterns were observed for several 
other human            T cell clones analyzed (unpublished data). In 
conclusion, the digitonin-solubilized human            TCR has a 
stoichiometry of TCR          CD3       2                   2  . 
  The mouse            TCR has a stoichiometry of TCR          CD3       2         2         2   
  The mouse            TCR was reported to lack CD3      (  10  ). We 
aimed to study mouse            TCR stoichiometry using our re-
agents and methods. Splenocytes from TCR            /       mice (  19  ) 
carrying transgenes for the TCRV     1.1 and TCRV     6 chains 
(TCR            /           1     6tg) (  20  ) served as a source of primary            T 
cells. Initially, we compared the            TCR from wild-type Bl/6 
mice with the            TCR from TCR            /           1     6tg mice by anti-      
immunopurifi  cation and anti-CD3      Western blotting (  Fig. 4 A  ).   
As expected, the            TCR did not contain CD3      (lanes 3 and 4). 
BN-PAGE showed that the digitonin-solubilized            TCR 
TCR and            TCR roughly contained equal amounts of CD3      
(lanes 4 and 8, when normalized to      ). The CD3      double 
band from            T cells exhibited a slower electrophoretic mo-
bility than that from            T cells (lanes 3 and 7). In addition, 
shorter       chains, which probably represent diff  erential mRNA 
splicing, were incorporated into the            TCR (lanes 7 and 8). 
In an earlier study, CD3      was not found associated with the 
           TCR from primary human T cells (  10  ). It is likely that, 
because of its diff  erent glycosylation, the            TCR  –  associated 
CD3      had similar mobility to CD3      and, therefore, could not 
be resolved when biotinylated proteins were detected by SDS-
PAGE and streptavidin Western blotting (  10  ). In conclusion, 
our data show that the human            TCR contains CD3      in 
cultured as well as in primary            T cells. 
  The human            TCR has a stoichiometry of TCR          CD3       2                   2   
  BN-PAGE is a method used to study the native structures of 
multiprotein complexes (  16  ). In our experiments, we used 
this technique to analyze the size of the human            TCR 
compared with that of the            TCR. After digitonin lysis of 
Jurkat and the human            T cell line Peer, as well as            T cell 
clones           19 and           46, TCRs were purifi  ed, separated by 
BN-PAGE, and detected by immunoblotting with an anti-      
antibody (  Fig. 3 A  ).   The            TCR, with a stoichiometry 
of TCR            CD3       2                   2   (  7, 8  ), had the same size as the            
TCR, suggesting a similar stoichiometry for the            TCR. 
Similar results were obtained from nonpurifi  ed TCRs (un-
published data). 
  To determine the stoichiometry of the human            TCR, 
we made use of the native antibody mobility shift (NAMOS) 
assay that we previously developed to determine the            TCR 
stoichiometry (  8, 17  ). The digitonin-extracted            TCR was 
incubated with diff  erent amounts of an anti-CD3      antibody, 
UCHT1, and then subjected to BN-PAGE (  Fig. 3 B  , lanes 2  –  4). 
At the highest antibody concentration, the            TCR shifted 
twice (lane 4, arrowhead labeled TCR 2Ab). This indicates 
that the            TCR has two binding sites for UCHT1, because 
  Figure 3.     The human            TCR has a stoichiometry of TCR          CD3       2                   2  . (A) The digitonin-solubilized          TCR is the same size as the          TCR. TCRs 
from Jurkat, Peer, and the          T cell clones         19 and         46 were purifi  ed, separated by BN-PAGE, and analyzed via Western blotting using the anti-      anti-
body. (B) Digitonin-extracted TCRs from          T cell clone         19 were incubated with the indicated amounts of antibodies against hCD3      (UCHT1),  hCD3    
(HMT3.2), hCD3      (APA1/2),       (G3), and hTCR         (5A6.E9), separated by BN-PAGE and analyzed as in A. The number of shifts correlates with the number of 
antibody binding sites in the TCR complex, as indicated by arrowheads. The marker protein is ferritin in its 24-meric (f1, 440 kD) and 48-meric (f2) forms.     JEM VOL. 204, October 29, 2007  2541
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not depicted), indicating that hCD3      can functionally replace 
mCD3      in the mouse            TCR, whereas mCD3      cannot. 
Sequence- and structure-wise, hCD3      is more related to 
mCD3      than to mCD3      (Fig. S3, available at http://www.jem
.org/cgi/content/  full/jem.20070782/DC1) (  24, 25  ). The 
property of hCD3      to replace mCD3      is probably indepen-
dent of the signal-trans  ducing immunoreceptor tyrosine-
based activation motif sequence of the cytoplasmic tail, because 
           T cell development is unaff  ected in mice lacking the CD3      
immunoreceptor tyrosine-based activation motif (  26  ). Thus, the 
functional diff  erences between hCD3      and mCD3      might map 
to the extracellular region, as the transmembrane regions are 
highly conserved between the diff  erent CD3 chains (Fig. S3). 
Indeed, the ectodomains are critical for TCR assembly, suggest-
ing that hCD3      can assemble within mouse TCR           to form a 
functional            TCR, whereas mCD3      cannot. This conclusion 
is in line with the fi  nding that mouse TCR      can assemble with 
hCD3           (  15  ), in contrast to mCD3          . 
  In our mice,            TCR expression was reduced to 60%, 
whereas that of            TCR was 80  –  100% of wild-type TCR levels. 
As in hCD3     -defi  cient patients (  Fig. 1  ), in CD3                 /      -
hCD3     tg mice, the            TCR expression level was less af-
fected by the absence of CD3      than that of the            TCR 
(  Fig. 5, E and F  ) when compared with wild-type mice. 
  The stoichiometries of human and mouse            TCRs cor-
relate well with the phenotypes for human and mCD3 de-
ficiencies. Mice lacking CD3      exhibit normal            T cell 
development (  6  ), consistent with the fi  nding that mCD3      is 
not part of the mouse            TCR (  9, 10  ). In contrast, CD3            /       
mice do not contain            T cells (  3  ), because CD3      is an oblig-
atory subunit of the mouse            TCR. In humans, both CD3      
and CD3      are part of the            TCR (  Figs. 2 and 3  ; and Fig. S1). 
CD3     -defi  cient            TCRs are still able to support            T cell 
development in humans (  Fig.1  ), likely because hCD3      can 
partially substitute for hCD3     . Remarkably, hCD3      is also 
has a similar mobility to the            TCR for which the stoi-
chiometry has been determined to be TCR          CD3       2                   2   
(  Fig. 4 B  , lanes 1,4, 6, and 8) (  8  ). To ascertain mouse            TCR 
stoichiometry, the NAMOS assay was applied using antibodies 
that had been controlled for specifi  city (Fig. S2 B). Anti-CD3    , 
as well as anti-CD3     , antibodies produced two shifts, indicating 
that the mouse            TCR contains two CD3           dimers (  Fig. 4 B  , 
lanes 6  –  11). Because CD3      always pairs with either CD3      
or CD      and because the mobility of the            TCR in BN-
PAGE was the same as that of the            TCR, we concluded that 
the digitonin-solubilized mouse            TCR has a stoichiometry 
of TCR          CD3       2         2         2  . This stoichiometry is in agreement 
with the conserved charge distributions in the transmembrane 
segments of the            and            TCR subunits and with the 1:2 
ratio of TCR          /CD3      in primary mouse            T cells (  21  ). 
  Mouse TCR      can bind to mouse CD3           (mCD3          ) but 
not to mCD3           (  9, 10, 21  ), whereas human TCR      binds 
both hCD3           and hCD3           (  15  ). These results are in agree-
ment with the diff  erent stoichiometries determined in our 
experiments for human and mouse            TCRs. 
  Human, but not mouse, CD3      can restore            T cell 
development in CD3     /CD3      double-defi  cient 
(CD3                 /      ) mice 
  We asked whether the diff  erent subunit requirements for 
mouse versus human            TCR formation were caused by 
  sequence diff  erences in their respective CD3      subunits. As 
expected, our CD3            /       and CD3                 /       mice both lack            
T cells (  Fig. 5 B   and not depicted) (  3, 22  ).   This was not caused 
by limiting amounts of CD3     , because a mCD3      transgene 
(mCD3     tg) could not rescue            T cell development (  Fig. 5 C  ). 
In contrast, the CD3                 /       mouse strain carrying an hCD3      
transgene (CD3                 /      hCD3     tg) (  23  ) has as many            T cells as 
wild-type mice (  Fig. 5, A and D  ). These cells could be detected 
in the thymus, spleen, lymph nodes, and blood (  Fig. 5   and 
  Figure 4.     The mouse            TCR has a stoichiometry of TCR          CD3       2         2         2  . (A) The          TCR on primary mouse          T cells does not contain CD3    .  TCRs 
from splenocytes from wild-type (Bl/6) and TCR         /       1    6tg mice were immunopurifi  ed with an anti-      antiserum. They were left untreated or were degly-
cosylated, separated via SDS-PAGE and analyzed by Western blotting as in   Fig. 2 (B and C)  . (B) The mouse          TCR has two CD3         dimers.  Splenocytes 
from wild-type (Bl/6) and TCR         /       1    6tg mice were lysed in digitonin, and purifi  ed TCRs were incubated with the indicated amounts of antibodies 
against CD3      (145-2C11) or CD3      (17A2), separated by BN-PAGE, and analyzed by Western blotting as in   Fig. 3  . Lanes 1, 4, 6, and 8 show TCRs alone. The 
number of shifts correlates with the number of antibody binding sites in the TCR complex, as indicated by arrowheads. The marker protein is ferritin in its 
24-meric (f1, 440 kD) and 48-meric (f2) forms.     2542 STOICHIOMETRY OF THE          TCR | Siegers et al.
           TCR stoichiometry is TCR          CD3       2         2         2  , as proposed by 
Hayes and Love (  21  ). Clarifi  cation of both mouse and human 
           TCR stoichiometries fi  nally explains the diff  erent pheno-
types observed in CD3-defi  cient humans and mice. We show 
that, in contrast to mCD3     , an hCD3      transgene is able to 
rescue            T cell development in mice lacking both mCD3      
and mCD3     . This indicates important structural and func-
tional diff  erences between hCD3      and mCD3      chains, as 
already suggested from the analysis of            T cells (  23  ). Indeed, 
the phenotype of CD3                 /      hCD3     tg mice (  Fig. 5  ) resem-
bles that of CD3     -defi  cient humans (  4, 23  ), as opposed to 
that of CD3            /       mice (  3  ). This is true for            (  23  ) as well as 
for            T cells (  Fig. 5  ). Thus, this humanized CD3     -defi  cient 
mouse strain may be a valuable tool to further study the im-
pact of CD3     -defi  ciency in            as well as            T cell patho-
physiology in humans. 
  MATERIALS AND METHODS 
  Cells, mice, and antibodies.    Human           and           T cell clones were generated 
as previously described (  28  ). TCR                 /       Jurkat cells transfected with V     9     2 
(J     9     2) were previously described (  15  ). Human PBMCs were isolated from a 
healthy donor using a Ficoll gradient. TCR            /       (  19  ) and V     1.1V     6tg mice 
(a gift of P. Pereira, Institut Pasteur, Paris, France) (  20  ), both on a C57BL/6 
able to rescue            T cell development in CD3                 /       mice, 
indicating its ability to substitute for mCD3      in the mouse            
TCR as well. In contrast, CD3     -defi  cient patients do not 
develop            T cells (  Fig. 1 A  ) (  5  ). Presumably, hCD3      cannot 
substitute for hCD3      in human            TCR formation and 
function. Along this line, replacement of the mTCR      connect-
ing peptide by the one of mTCR      promotes the exclusion of 
mCD3      from the complex (  27  ), suggesting that the connect-
ing peptide of mTCR      is involved in the association with 
CD3      but does not permit the assembly of CD3     . A diff  er-
ence in the connecting peptide sequences of human and mouse 
TCR      could be responsible for the diff  erential involvement 
in            TCR assembly of CD3      in both species. 
  Conclusions 
  Using both conventional immunopurifi  cation followed by 
Western blotting and our novel NAMOS assay, we have 
determined the human digitonin-solubilized           TCR stoichi-
ometry to be TCR          CD3       2                   2  . The CD3      chain is diff  er-
entially glycosylated depending on its association with the            
or the            TCR (  11  ), likely accounting for contradictory 
results previously reported (  10, 12  ). We show that the mouse 
  Figure 5.     hCD3      can substitute both mCD3      and mCD3      in            T cell development. Thymocytes and splenocytes from wild-type (A), CD3         /    
(B), CD3            /    mCD3    tg (C), and CD3            /    hCD3    tg (D) mice were surface stained with anti-CD3 (145-2C11) and anti-TCR         (GL3) antibodies and analyzed 
by fl  ow cytometry. Percentages of cells in the marked regions and the total number of          T cells (in millions) in the thymi are shown within and above the 
dot plots, respectively. (E) CD3 expression is higher on CD3    -defi  cient          than          T cells. Flow cytometry histograms of anti-CD3 (2C11)  –  stained 
CD3            /    hCD3    tg T cells (dashed lines) are compared with wild-type mice (continuous lines) either in          (top) or          (bottom) T cells from the thymus 
(left) or spleen (right). (F) Quantifi  cation of the CD3 expression on          or          T cells from CD3            /    hCD3    tg mice as a percentage of that on the same cell 
types from wild-type mice (percentage of CD3 expression). The CD3 high population was used for the          TCR in thymocytes. Data are expressed as the 
percent mean fl  uorescence intensity       SEM from two independent experiments. *, P       0.05 compared with          T cells. mio, millions.     JEM VOL. 204, October 29, 2007  2543
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